Remove COVID-19 Remove Pharmaceutical Industry Remove World Health
article thumbnail

COVID-19 Showcased Failed Global Cooperation

Bill of Health

By Kayum Ahmed, Julia Bleckner, and Kyle Knight In mid-May, the World Health Organization officially declared the “emergency” phase of the COVID-19 pandemic over. As reasonable and evidence-based adjustments to prevent transmission and protect health became the norm, authorities continued to fail on equity.

COVID-19 303
article thumbnail

No Take-Backs: Moderna’s Attempt to Renege on its Vaccine Patent Pledge

Bill of Health

On October 8, 2020, Moderna, the maker of one of the first mRNA-based vaccines for COVID-19 and the recipient of billions of dollars of U.S. As a result, it publicly promised that “ while the pandemic continues, Moderna will not enforce our COVID-19 related patents against those making vaccines intended to combat the pandemic.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Case for Procurement Transparency

Bill of Health

By Tara Davis and Nicola Soekoe In January 2021, the Director General of the World Health Organization (WHO) observed that the world was on the brink of a “catastrophic moral failure” if wealthier nations did not ensure the equitable distribution of COVID-19 vaccines. This, critically, could have helped save lives.

article thumbnail

Unseen Scars: The Devastating Impact of Corruption on Mental Health Systems in Low and Middle-Income Countries

Bill of Health

This is a massive blind spot, as mental health problems are a growing concern worldwide. The experience of COVID-19 is estimated to have led to a 27.6% Low and middle-income countries (LMICs), home to 80% of people with mental illnesses, should prioritize strengthening their mental health systems.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2024

SQA

It provides a practical guide for the pharmaceutical industry on how to implement PACs within the framework of an effective Pharmaceutical Quality System (PQS) and in alignment with ICH quality guidelines. Recommendations for stability studies.

FDA 52